Weekly paclitaxel in advanced non[ndash ]small cell lung cancer

Chang, A. Y.; Rubins, Jonathan; Asbury, Robert F.; Boros, László G.; Hui, Lai Fong

doi:10.1053/sonc.2001.27607

Cited by 55 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Historically, response rates of 10% to 15% are seen when using single agent paclitaxel to treat advanced NSCLC (49,50). In contrast, the clinical benefit rate for matuzumab F paclitaxel in our study cohort was significantly higher (f60%), suggesting an additive or synergistic effect of this drug combination.…”

Section: Discussioncontrasting

confidence: 52%

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Schittenhelm

Kollmannsberger

Oechsle

et al. 2009

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Antibodies targeting epidermal growth factor receptor (EGFR) have proven to be effective in patients with nonsmall cell lung cancer (NSCLC) that express EGFR. We recently published a phase I study of weekly matuzumab plus paclitaxel. This therapy was well tolerated and showed clinical responses in the majority of patients. Although matuzumab displays potent antitumor activity in some patients, not all patients respond well to treatment. Whether dysregulation of EGFR-mediated pathways precludes or sensitizes cells to paclitaxel is unknown. We sought to determine molecular predictive factors for therapy response in a phase

show abstract

Section: Discussioncontrasting

confidence: 52%

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Schittenhelm

Kollmannsberger

Oechsle

et al. 2009

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Furthermore, the performance and staging statuses of the study population predicted a major part of the treatment results: the better the performance status and staging status of the study population, the better the response rate and the survival, and also the less severe the treatment toxicities. Weekly paclitaxel treatment has been found to have a higher response rate and better toxicity profiles in many phase II studies of both chemonaïve patients and patients who have failed previous chemotherapy (Akerley et al, 1998;Belani, 2001;Chang et al, 2001;Koumakis et al, 2002). However, there has been no randomised trial comparing weekly paclitaxel plus cisplatin vs other new anticancer drugs plus cisplatin.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, we performed this phase II randomised trial. The weekly dose of paclitaxel single-agent treatment given to the patient can be 90 mg m À2 or higher (with/ without carboplatin or concomitant radiotherapy) (Belani, 2001;Chang et al, 2001;Koumakis et al, 2002), even up to 175 mg m À2 week À1 for 6 of 8 weeks (Akerley et al, 1998). However, there has been no report of a weekly dose of paclitaxel in combination with cisplatin.…”

Section: Discussionmentioning

confidence: 99%

“…The dosage and schedule of the paclitaxel used varied widely among the different studies and, thus, probably had different therapeutic effects on the patients. In contrast to the conventional paclitaxel treatment schedule of once every 3 or 4 weeks, weekly paclitaxel treatment was found to have a higher response rate and better toxicity profiles in phase II trials of both chemonaïve patients and patients who had failed previous chemotherapy (Akerley et al, 1998;Belani, 2001;Chang et al, 2001;Koumakis et al, 2002). However, there has been no report of randomised phase II or III trials comparing weekly paclitaxel with other new anticancer drugs.…”

mentioning

confidence: 97%

See 1 more Smart Citation

A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

Shih

et al. 2004

Br J Cancer

View full text Add to dashboard Cite

Phase II studies have suggested that weekly paclitaxel has a higher response rate and better toxicity profile than the conventional schedule of once every 3 or 4 weeks. Our aim was to evaluate the efficacy of weekly paclitaxel plus cisplatin (PC) vs vinorelbine plus cisplatin (VC) in chemonaïve non-small-cell lung cancer (NSCLC) patients. From October 2000 to May 2002, 140 patients were enrolled. The treatment dose was P 66 mg m À2 intravenous infusion (i.v.) on days 1, 8, and 15, and C 60 mg m À2 i.v. on day 15, or V 23 mg m À2 i.v. on days 1, 8, and 15, and C 60 mg m À2 i.v. on day 15, every 4 weeks. In all, 281 cycles of PC and 307 cycles of VC were given to the patients in the PC and VC arms, respectively. There were 26 partial responses and one complete response (overall 38.6%) in the PC arm, and no complete responses, but 27 partial responses (overall 38.6%) in the VC arm. Myelosuppression was more common in the VC arm (Po0.001). Peripheral neuropathy and myalgia were significantly more common in the PC arm (Po0.001). The median time to disease progression was 6 months in the PC arm and 8.4 months in the VC arm (P ¼ 0.0344). The median survival time was 11.7 months in the PC arm and 15.4 months in the VC arm (P ¼ 0.297). We concluded that weekly PC is not suggested for NSCLC patients due to the relatively shorter progression-free survival and more common nonhaematological toxicities.

show abstract

“…Paclitaxel is a diterpenoid natural product (Wani et al 1971) isolated from the Pacific Yew (Taxus brevifolia ) that has demonstrated significant antitumor activity against various solid tumors, including advanced ovarian carcinoma, metastatic breast cancer, nonsmall cell lung cancer, and head and neck carcinomas (Chang et al 2001;Ishitobi, Shin, and Kikkawa 2001;Zhang et al 2005b). Due to its low aqueous solubility (less than 2 µg/mL), paclitaxel is currently formulated in a vehicle composed of a 1:1 blend of Cremophor R EL (polyethoxylated castor oil) and ethanol, which is diluted 5-20-fold in normal saline or dextrose solution (5%) for administration.…”

mentioning

confidence: 99%

Liposome Formulation of Paclitaxel with Enhanced Solubility and Stability

et al. 2007

View full text Add to dashboard Cite

Despite its strong antitumor activity, paclitaxel (Taxol R ) has limited clinical applications due to its low aqueous solubility and hypersensitivity caused by Cremophor R EL and ethanol which is the vehicle used in the current commercial product. In an attempt to develop a pharmaceutically acceptable formulation that could replace Taxol R , a paclitaxel incorporated liposome has been constructed to improve solubility and physicochemical stability. The effect of various components of the liposome, including cholesterol and lipid, on the solubility and entrapment efficiency (EE) of paclitaxel was systematically investigated. The results showed that 5% (v/v) of polyethylene glycol 400 in the hydration medium of liposome significantly increased the solubility (up to 3.39 mg/mL) as well as the EE and the paclitaxel content in the liposome formulation composed of 10% (w/v) of S 100 PC with cholesterol (cholesterolto-lipid molar ratio = 10:90). When sucrose (sugar-to-lipid molar ratio = 2.3) was added as a lyoprotectant during the freeze-drying of the liposome, physicochemical stability of liposome was significantly improved. Moreover, the cytotoxicity of the final liposome formulation against MDA-MB-231 human breast cancer cell line was not significantly different from that of Taxol R . The enhanced aqueous solubility as well as the physicochemical stability of paclitaxel in the liposome formulation developed in this study could be a safer and effective alternative to the Cremophor R EL and ethanol formulation.

show abstract

Weekly paclitaxel in advanced non[ndash ]small cell lung cancer

Cited by 55 publications

References 13 publications

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer

A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

Liposome Formulation of Paclitaxel with Enhanced Solubility and Stability

Contact Info

Product

Resources

About